Familial Mediterranean fever
Also known as: Family, Familial, Genetic, Inherited
Methodology & AI Transparency ⓘ
Familial Mediterranean fever Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Familial Mediterranean fever (also termed Family or Familial)—coded clinically as M04.1 across Arthritis & Joints guidelines—combines serum urate/inflammatory marker in Familial Mediterranean fever (M04.1: profiling) with structured follow-up of Serum Uric Acid in Familial Mediterranean fever (M04.1: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M04.1)).
- 2 Real-world patient consensus: Clinical coding for Familial Mediterranean fever uses ICD-10 M04.1 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Clinicians assessing Familial Mediterranean fever focus on monosodium urate or in Familial Mediterranean fever (M04.1: calcium pyrophosphate crystal) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Familial Mediterranean fever: Weight-Bearing Joint Radiograph [Familial Mediterranean fever M04.1] (Preserved joint-space width (M04.1)) and Serum Uric Acid in Familial Mediterranean fever (M04.1: (Gout Target)).
Ask our AI Specialists anything about Familial Mediterranean fever
What Is Familial Mediterranean fever?
Familial Mediterranean fever (also termed Family or Familial)—coded clinically as M04.1 across Arthritis & Joints guidelines—combines serum urate/inflammatory marker in Familial Mediterranean fever (M04.1: profiling) with structured follow-up of Serum Uric Acid in Familial Mediterranean fever (M04.1: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M04.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Familial Mediterranean fever (ICD-10 M04.1) is driven by monosodium urate or in Familial Mediterranean fever (M04.1: calcium pyrophosphate crystal); specialists in Osteoarthritis, Gout & Joint Pain monitor Serum Uric Acid in Familial Mediterranean fever (M04.1: (Gout Target)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Familial Mediterranean fever (M04.1): localized tendon or in Familial Mediterranean fever (M04.1: bursa tenderness limiting)
- • Secondary Familial Mediterranean fever clinical sign: activity-related deep aching in Familial Mediterranean fever (M04.1: joint pain in)
- • Symptom flares in Familial Mediterranean fever correlating with Weight-Bearing Joint Radiograph [Familial Mediterranean fever M04.1] deviation outside Preserved joint-space width (M04.1)
- • Functional arthritis & joints impact requiring serum urate/inflammatory marker in Familial Mediterranean fever (M04.1: profiling) evaluation (M04.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Familial Mediterranean fever Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M04.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Familial Mediterranean fever M04.1] | Preserved joint-space width (M04.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Familial Mediterranean fever (M04.1: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M04.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Familial Mediterranean fever (M04.1: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M04.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Familial Mediterranean fever
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Colchicine Gloperba, Colcrys • RxCUI 197541 | Alkaloid | 76% | $0.1182 | $ 6.52 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Familial Mediterranean fever)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long-Term safety and real-world benefits of Bempedoic Acid in Patients With: What a 1,462-Participant Study Found Bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment. The American journal of cardiology • 2022-07-01 • Phase III Randomized Trial | N = 1,462 | 96/100 | PMID 35483979 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ezetimibe coadministered with atorvastatin or simvastatin Ezetimibe coadministered with atorvastatin or simvastatin in patients with HoFH produced clinically important LDL-C reductions compared with best current therapy. Circulation • 2002-05-28 • Randomized Controlled Trial | N = 25 | 88/100 | PMID 12034651 ↗ |
| Rosuvastatin vs. Atorvastatin: Which Works Better for Heterozygous familial high cholesterol? Both treatments were well tolerated. The American journal of cardiology • 2003-12-01 • Randomized Controlled Trial | N = 187 | 88/100 | PMID 14636905 ↗ |
| Can This Approach Help? Inside the Latest Research on Atorvastatin: an effective lipid-modifying agent in familial high One subject withdrew for personal reasons. Arteriosclerosis, thrombosis, and vascular biology • 1997-08-15 • Randomized Controlled Trial | N = 22 | 88/100 | PMID 9301631 ↗ |
| Can This Approach Help? Inside the Latest Research on A dose-titration and comparative study of rosuvastatin and atorvastatin in All treatments were well tolerated. Atherosclerosis • 2008-03-15 • Randomized Controlled Trial | N = 21 | 88/100 | PMID 17727860 ↗ |
Familial Mediterranean fever Patient Community & “People Like Me” Threads
Filter Familial Mediterranean fever community threads and patient logs by age, biological sex, dosage, and treatment duration.